Parkinson's pain: could a new Add-On drug bring relief?

NCT ID NCT07761936

Recruiting now Symptom relief Sponsor: Universita di Verona Source: ClinicalTrials.gov ↗

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This clinical trial tests whether safinamide, an add-on medication, can reduce chronic pain in people with Parkinson's disease who also experience motor fluctuations. About 60 adults with Parkinson's and pain lasting over three months will receive either safinamide or a placebo for 12 weeks, alongside their usual levodopa treatment. The study measures changes in pain intensity and other symptoms to see if safinamide offers meaningful relief.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: safinamide
What this could lead to: If safinamide proves effective, it could offer a new way to manage chronic pain in Parkinson's disease, improving quality of life for many patients.
What could go wrong: This is a phase 3 trial with 60 participants, so results may not apply to all patients. Safinamide may not reduce pain more than placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PAIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

agnosia Pain Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PAIN PAIN MANAGEMENT PARKINSON DISEASE (DISORDER) PARKINSON DISEASE (PD)

Contacts and locations

Locations

Azienda ospedaliera universitaria integrata verona
RECRUITING

Verona, Veneto, 37134, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.